Search results
Showing 251 to 298 of 298 results for breast cancer
This appraisal has been updated and replaced by NICE guideline CG81.
This advice has been updated and replaced by NICE diagnostics guidance 34.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
This guideline covers how to assess and monitor body weight and how to prevent someone from becoming overweight or obese before, during and after pregnancy. The aim is to help all women who have a baby to achieve and maintain a healthy weight by adopting a balanced diet and being physically active.
This guidance has been updated and replaced by NICE technology appraisal guidance 816.
This guidance has been updated and replaced by NICE technology appraisal guidance TA421.
This guideline covers behaviours such as diet and physical activity to help children (after weaning), young people and adults maintain a healthy weight or help prevent excess weight gain. The aim is to prevent a range of diseases and conditions including cardiovascular disease and type 2 diabetes and improve mental wellbeing.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Weight management: lifestyle services for overweight or obese adults (PH53)
This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
This guideline covers how local communities, with support from local organisations and networks, can help prevent people from becoming overweight or obese or help them lose weight. It aims to support sustainable and community-wide action to achieve this.
Developing NICE guidelines: the manual
Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).
NICE draft updated guideline recommends more treatment choices for menopause symptoms
New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.
A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term and is now enshrined in NICE guidance.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body.
An estimated 100 people per year with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) following the final draft recommendation from NICE.
NICE draft guidance does not recommend tucatinib for advanced breast cancer
NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.
NICE draft guidance recommends abemaciclib for advanced breast cancer
NICE has today published draft guidance which recommends twice-daily pill abemaciclib (also called Verzenios and made by Eli Lilly) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
Uptake of NICE-approved medicines on the NHS to treat cardiovascular disease, diabetes and osteoporosis is higher than expected, latest figures reveal.
NICE has welcomed proposed new guidelines on alcohol which aim to limit the health risks that result from drinking.
NICE approves routine use of drug combination for advanced breast cancer
Another life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS following its approval by NICE in final draft guidance published today (23 September 2022).
Draft guidance published today (8 March 2022) by NICE for public consultation does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer that has spread to other parts of the body.
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
Decisions around whether to offer a person surgical treatment should not be based on age and fitness, according to a new report.
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread, after the technology was recommended in draft NICE guidance.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
NICE recommends step-change targeted treatment for people with early breast cancer
Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has today, 7 April 2022, issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
NICE final draft guidance adds further treatment option for triple-negative breast cancer
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
Ground-breaking commercial deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit in final draft guidance published today (6 April 2023) by NICE that recommends it for some types of early breast cancer and advanced prostate cancer.
NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
Price discount helps give green light for breast cancer drug pertuzumab
NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink tumours in some people with breast cancer so surgery can take place.
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE today (26 February) recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
premature ovarian insufficiency and women with hormone-sensitive cancer (for example, breast cancer). This guideline is...
What are the options for women with inherited breast cancer?
Following Angelina Jolie?s decision to go public with the news that she has had a double mastectomy for breast cancer, we explore who is at risk and the treatment options available for women on the NHS.
Thousands of lives in England could be saved each year if the NHS follows updated guidance to help it diagnose cancer earlier. Here we outline what the guidance means for GPs.